Articles On LBT Innovations (ASX:LBT)
| Title | Source | Codes | Date |
|---|---|---|---|
|
LBT Innovations (ASX:LBT) partners with AstraZeneca for APAS Pharma development
LBT Innovations (LBT) pens a deal with AstraZeneca to undertake full product development of its APAS Pharma artificial intelligence software The APAS Pharma analysis module will be developed to identify microbial growth on settle plates... |
themarketherald.com.au | LBT | 2 years ago |
|
Overnight signs that US inflation is easing: Aus shares 1% higher at noon
ShareCafeOvernight signs that US inflation is easing: Aus shares 1% higher at noon by Peter Milios At noon, all sectors across the ASX are higher, after the release of the December jobs report data, as well as an economic activity survey.... |
ShareCafe | LBT | 2 years ago |
|
Stocks of the Hour: LBT, ESS, SBR
ShareCafeStocks of the Hour: LBT, ESS, SBR LBT Innovations (ASX:LBT) has been engaged by AstraZeneca to undertake a full product development project for LBT’s new APAS Pharma analysis module, which will be used on t... |
ShareCafe | LBT | 2 years ago |
|
ASX Health Stocks: LBT Innovations picked by AstraZeneca as partner, share price surges 22pc
LBT Innovati0ns engaged by global pharma company, AstraZeneca Volpara nabs $7m plus contracts Imugene receives ethics approval for Vaxinia LBT to partner with AstraZeneca LBT Innovations (ASX:LBT) surged 22%% this morning after announci... |
Stockhead | LBT | 2 years ago |
|
Stocks of the Hour: LBT Innovations, Essential Metals, Sabre Resources
09 Jan 2023 - A snapshot of the stocks on the move, featuring LBT Innovations, Essential Metals and Sabre Resources. |
FNN | LBT | 2 years ago |
|
LBT Innovations to partner with AstraZeneca on development of APAS Pharma microbial monitoring product
This content is created by Smallcaps Authors. [Author : Imelda Cotton] Australian medical technology company LBT Innovations (ASX: LBT) will partner with global biopharmaceutical firm AstraZeneca for the full product development of its AP... |
SmallCaps | LBT | 2 years ago |
|
Top 10 at 10: These ASX lithium and helium stocks are looking monstrous on Monday morning
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | LBT | 2 years ago |
|
CLOSING BELL: Because it’s time to go home when the ferris wheel breaks
ASX takes a pre-Christmas bath, dragged down by InfoTech and Discretionary Asian markets fall lower today as Japan widens yield target range PolarX is still ruling the playground after one of the big kids said it was cool With apologies t... |
Stockhead | LBT | 2 years ago |
|
Stocks of the Hour: Avecho Biotechnology, LBT Innovations, Meteoric Resources
20 Dec 2022 - A snapshot of the stocks on the move featuring Avecho Biotechnology (ASX:AVE), LBT Innovations (ASX:LBT) and Meteoric Resources (ASX:MEI). |
FNN | LBT | 2 years ago |
|
LBT Innovations subsidiary appoints APAS Independence distributor for Europe
Australian medical technology company LBT Innovations (ASX:LBT) has announced the appointment of Thermo Fisher Scientific as the exclusive distributor for the APAS Independence in Europe. |
BiotechDispatch | LBT | 2 years ago |
|
LBT Innovations (ASX:LBT) appoints Thermo Fisher as European distributor of APAS Independence
LBT Innovations (LBT) appoints Thermo Fisher Scientific as its exclusive distributor for the APAS Independence product in EuropeThe move expands LBT’s existing distribution agreement for the APAS Independence to include up to 35 countries g... |
themarketherald.com.au | LBT | 2 years ago |
|
Oil falls to lowest price since 2021: ASX closes 0.42% lower
ShareCafeOil falls to lowest price since 2021: ASX closes 0.42% lower by Peter Milios Amidst the ongoing tensions arising from the continuation of China’s lockdowns from their recent COVID surge, oil has fallen to its lowest point since D... |
ShareCafe | LBT | 3 years ago |
|
China’s lockdown rampage causes lower start to ASX
ShareCafeChina’s lockdown rampage causes lower start to ASX by Peter Milios China’s persistent lockdowns have caused commodity prices and futures to fall. As a result, at noon, the S&P/ASX 200 is 0.34 per cent or 24.50 points lower at... |
ShareCafe | LBT | 3 years ago |
|
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | LBT | 3 years ago |
|
Top 10 at 10: These ASX rare earths, lithium and green hydrogen stocks are thrilling punters today
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | LBT | 3 years ago |
|
Closing Bell: Sezzle’s got some zip, Zip’s got some sizzle and Openpay’s TTV jumps 50%
ASX200 and small caps end about 0.4% down BNPLs come out of hibernation WA1 is finding even more niobium Local markets failed to launch on Wednesday, unlike the missile strikes early this morning AEDT, which reportedly crossed the borde... |
Stockhead | LBT | 3 years ago |
|
Webinar Recap – EMH, MCL, WML & LBT
ShareCafeWebinar Recap – EMH, MCL, WML & LBT Catch up on the full webinar presentations from European Metals (ASX: EMH), Mighty Craft (ASX: MCL), Woomera Mining (ASX: WML) & LBT Innovations (ASX: LBT) Webinar Recap – EMH, MCL, WML... |
ShareCafe | LBT | 3 years ago |
|
LBT Innovations (ASX: LBT) – Webinar Presentation
ShareCafeLBT Innovations (ASX: LBT) – Webinar Presentation Brent Barnes – Managing Director & CEO – LBT Innovations is a groundbreaking designer of advanced technology solutions for the medical industry. LBT Innovations (ASX: LBT) – We... |
ShareCafe | LBT | 3 years ago |
|
Top 10 at 10: ASX rare earths and lithium stocks dominate at the open, once again
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | LBT | 3 years ago |
|
Strong finish despite tomorrow’s expected rate hike: ASX closes 1.15% higher
ShareCafeStrong finish despite tomorrow’s expected rate hike: ASX closes 1.15% higher by Peter Milios All eyes are on tomorrow’s expected interest rate hike, with many predicting a 50 basis point rise. To finish the day the S&P/ASX 20... |
ShareCafe | LBT | 3 years ago |
|
IT sector rallies to lift the market: ASX up 0.94% at noon
ShareCafeIT sector rallies to lift the market: ASX up 0.94% at noon The local market has commenced the week in the green with the S&P/ASX 200 up 0.94 per cent or 63.70 points higher to 6,849.40 at noon. This comes off the back of US equ... |
ShareCafe | LBT | 3 years ago |
|
Energy and Materials only sectors left lagging: ASX closes 0.28% higher
ShareCafeEnergy and Materials only sectors left lagging: ASX closes 0.28% higher by Peter Milios In today’s events, independent commission agency ASIC has launched legal action against BPS Financial, the company behind Gold Coast-based di... |
ShareCafe | LBT | 3 years ago |
|
Closing Bell: C29 goes interstellar on Argentine-brine; Benchmark stays afloat on light volumes ahead of Budget and CPI
The ASX 200 trims gains to end circa 0.3% higher Small caps drop 0.2%, but C29 Metals booms China markets still choppy after political appointments The big show, if balancing books and picking pre-chosen soundbytes is your thing, begins... |
Stockhead | LBT | 3 years ago |
|
Optimism out of the US boosts sentiment: ASX up 0.6% at noon
ShareCafeOptimism out of the US boosts sentiment: ASX up 0.6% at noon by Lauren Hayes Positive gains in the local market have extended into a second day as optimism out of the US about corporate earnings ahead of several key tech reports... |
ShareCafe | LBT | 3 years ago |
|
IT and Materials lead the way: ASX finishes 1.54% higher
ShareCafeIT and Materials lead the way: ASX finishes 1.54% higher by Peter Milios All sectors finished in the green to start the week, with some big results from Australian electric vehicle companies. The ASX companies that were amongst t... |
ShareCafe | LBT | 3 years ago |
|
Monday morning rally: ASX up 1.73% at lunch
ShareCafeMonday morning rally: ASX up 1.73% at lunch by Lauren Hayes The Australian market is enjoying a solid start to the trading week after US equities snapped their two-day losing streak and posted solid gains on more strong corporate... |
ShareCafe | LBT | 3 years ago |
|
Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?
We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month There were 191 ASX IPOs in... |
Stockhead | LBT | 3 years ago |
|
LBT Innovations (ASX: LBT) Developing Clean-Room Technology for Pharma Companies
ShareCafeLBT Innovations (ASX: LBT) Developing Clean-Room Technology for Pharma Companies LBT Innovations Limited (ASX: LBT) CEO and Managing Director Brent Barnes discusses new opportunities for the company’s automation technology. LBT In... |
ShareCafe | LBT | 3 years ago |
|
ScoPo’s Powerplays: Taps on again with ASX health stocks in BIG capital raises
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX Powerplays. Several ASX health stocks have... |
Stockhead | LBT | 3 years ago |
|
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F... |
Stockhead | LBT | 3 years ago |
|
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m... |
Stockhead | LBT | 3 years ago |
|
Cast your eyes over these 15 weird and wonderful biotech stocks we found on the ASX
Avita Medical makes spray on skin for burns and soft tissue injuries HITIQ’s concussion tech is popular for athletes and sports teams PainChek’s smartphone app can tell if babies or older Aussies are in pain There’s a plethora of biotech... |
Stockhead | LBT | 3 years ago |
|
Dr Boreham’s Crucible: With sales success, does LBT have the world on a plate?
For most medical device companies, selling six instruments within the space of six months would hardly be cause for celebration. But for the Adelaide-based LBT Innovations (ASX:LBT), the sales “inflexion point” was an excuse to crack open a... |
Stockhead | LBT | 3 years ago |
|
ScoPo’s Powerplays: Health stocks tumble but half-price sale presents buying opportunities
Healthcare and life sciences expert Scott Power – a senior analyst with Morgans Financial for 24 years – on what the movers and shakers have been doing in health and which ASX health stocks make Scott’s Powerplays. Are you the cuddly type?... |
Stockhead | LBT | 3 years ago |
|
Closing Bell: Interest piqued? Not for sliding local markets on Rates Day
The interest rate rise came and the markets fell, then turned a corner. The question now is — will the wheels stay on? Already lagging, the ASX Emerging Companies (XEC) index has closed 0.8% lower. The benchmark has closed 0.4% behind. The... |
Stockhead | LBT | 3 years ago |
|
Check Up: Money managers are still bullish on Healthcare; here’s what they said
The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week Dr Anthony Faucci, America’s top infectious disea... |
Stockhead | LBT | 3 years ago |
|
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot... |
Stockhead | LBT | 3 years ago |
|
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?
Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve... |
Stockhead | LBT | 3 years ago |
|
ScoPo’s Powerplays: ‘We’ve gone from a boiled lolly to a prize-winning chocolate in the space of a week’
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. At the start of trade on Frida... |
Stockhead | LBT | 3 years ago |
|
Closing Bell: Any price is totally right
The ASX Emerging Companies Index (XEC) has ended 1.5% higher on Wednesday, driven by a new EV car as a few battery metal small caps locked in the right prices from a government ready to pay. The ASX200 has also risen a further 1.1% driven b... |
Stockhead | LBT | 3 years ago |
|
LBT Innovations (ASX:LBT) subsidiary CCS secures US order for APAS instruments
LBT Innovations’ (LBT) wholly owned subsidiary Clever Culture Systems (CCS) receives purchase orders for five APAS Independence instruments from its US-based distributor Thermo Fisher Scientific It comes after LBT acquired the remainder of... |
themarketherald.com.au | LBT | 3 years ago |
|
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month
Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal... |
Stockhead | LBT | 3 years ago |
|
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX
The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby... |
Stockhead | LBT | 3 years ago |
|
Webinar Recap – TNR, LBT, 1AD & LIT
ShareCafeWebinar Recap – TNR, LBT, 1AD & LIT Catch up on the full webinar with presentations from Torian Resources (ASX: TNR), LBT Innovations (ASX: LBT), Adalta (ASX: 1AD) & Lithium Australia (ASX: LIT) Webinar Recap – TNR... |
ShareCafe | LBT | 3 years ago |
|
LBT Innovations (ASX: LBT) – Webinar Presentation
ShareCafeLBT Innovations (ASX: LBT) – Webinar Presentation Brent Barnes – CEO & Managing Director – LBT Innovations is a groundbreaking designer of advanced technology solutions for the medical industry. LBT Innovations (ASX: LBT) – We... |
ShareCafe | LBT | 3 years ago |
|
ScoPo’s Powerplays: For healthcare, a case of nerves ahead of reporting season
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week There’s so... |
Stockhead | LBT | 3 years ago |
|
LBT Innovations (ASX:LBT) completes CCS acquisition
LBT Innovations (LBT) completes the acquisition of Clever Culture Systems (CCS) and now owns 100 per cent On December 29, the company signed a binding agreement with Hettich to acquire its 50 per cent holding in CCS The acquisition consi... |
themarketherald.com.au | LBT | 3 years ago |
|
ASX Health Stocks: Imugene levels up in Phase 1 trial, Imricor slides into Greece
The ASX 200 Health Index (XHJ) is trading higher by 0.30% at the time of writing, compared to the broader index which is also up by 0.87%. Imugene (ASX:IMU) is up by 8% this morning, after confirming that its immunotherapy candidate, PD1-Va... |
Stockhead | LBT | 3 years ago |
|
10 at 10: These ASX stocks are finishing the year with a blinder of a day this morning
Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov... |
Stockhead | LBT | 3 years ago |
|
Check Up: As Omicron rages, rapid antigen testing specialist Atomo surges nearly 50pc
At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform... |
Stockhead | LBT | 3 years ago |